Track topics on Twitter Track topics that are important to you
Signed Master Service Agreement With Leading Pharmaceutical Company
Record Volume of MyPRS® Tests Sold to Hospitals Outside of the University of Arkansas for Medical Sciences (UAMS)
CARLSBAD, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today reported recent achievements and financial results for the second quarter ended June 30, 2015.
Samuel D. Riccitelli, Signal's President and Chief Executive Officer, commented, "Our team has continued to work hard and make advancements in the execution of our business plan. Importantly, we entered into a MSA with a leading pharmaceutical company for the use of MyPRS®, our proprietary genetic test, in ongoing and upcoming clinical trials for new therapies to treat multiple myeloma. In addition, we recently announced that our test will be offered through America's Choice Provider Network which we expect will facilitate reimbursement of MyPRS® for patients in their network. Steps such as these are integral to our strategy and long-term growth as they provide opportunities to increase revenue outside of our relationship with the University of Arkansas for Medical Sciences, which has traditionally been the majority of our business."
Mr. Riccitelli continued, "We continue to build momentum in sales to U.S. hospitals other than UAMS, achieving a 70% year over year increase for these tests which were billed during the quarter. This is a direct result of our sales force expansion and increased marketing efforts, and we are excited to see the growing interest in MyPRS®. However, due to the funding available for research programs at UAMS, we have continued to face declining revenues in this portion of our business, a trend which we expect to continue to see going forward. It is important to note that our long-term plan has always been to grow the business beyond our ongoing strategic relationship with UAMS. These efforts have continued to progress well, with sales to hospitals outside of UAMS reaching record volume during the quarter and with agreements such as the MSA that we recently signed."
Second Quarter 2015 Financial Results
Tests billed for U.S. hospitals outside of UAMS for the second quarter of 2015 increased 70% to 187 over the second quarter of 2014 reflecting the continued execution of our long-term strategy. The company expects the expanded sales and marketing efforts and an increase in new hospital customers to continue to fuel this upward trend.
Total test orders for the second quarter of 2015 decreased 24% to 770 when compared to the second quarter of 2014. The decrease is attributable to the decrease in the number of tests billed for UAMS research and clinical patients at the university. Signal expects continued downward pressure on revenue from the UAMS research programs due to a reduction in research funds available at UAMS.
Net revenue for the second quarter of 2015 decreased to $734,000, or 42%, compared to $1.3 million during the second quarter of 2014. The decrease is primarily attributable to the aforementioned decline in tests sourced from UAMS and a reduction in reimbursement estimates used to calculate revenue for billings to non-contracted insurance payors. The latter is a more conservative posture based on our collection experiences and an increase in the number of new non-contracted payors with whom the company has no payment history.
Cost of revenue for the second quarter of 2015 was $678,000 compared to $954,000 during the second quarter of 2014. This decrease was attributable to a reduction in personnel costs related to decreased stock based compensation expenses and a decrease in material and supply costs due to the decrease in total tests performed.
Research and development expenses totaled approximately $194,000 for the second quarter of 2015 compared to approximately $128,000 during the second quarter of 2014. The increase in research and development was primarily attributable to increased costs associated with the usage of labor, materials, and supplies for the company's internal research projects.
Selling and marketing expenses were $574,000 for the second quarter of 2015 compared to $66,000 during the second quarter of 2014. The increase in selling and marketing expenses was primarily attributable to personnel costs associated with the expansion of our sales and marketing function and establishing managed care, commercial and business development functions.
General and administrative expenses were $1.8 million for the second quarter of 2015 compared to $2.9 million during the second quarter of 2014. The decrease in general and administrative expenses was primarily attributable to a decrease in stock-based compensation expenses which was partially offset by increased personnel costs related to hiring certain executive officers, internal billing, IT, and administrative staff, and expenses related to being a publicly-traded company.
Basic and diluted net loss per common share for the quarter ended June 30, 2015 was approximately $(0.33) per share based on 7,785,670 shares outstanding. Basic and diluted net loss per common share for the quarter ended June 30, 2014 was approximately $(4.73) per share based on 695,454 shares outstanding.
As of June 30, 2015, the company had cash of $10.4 million and working capital of $9.8 million.
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010.
Safe Harbor Statement
This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "may," "will," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding our ability to achieve profitability and to penetrate the market opportunity that we believe exists for our prognostic genetic test. Such forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from those discussed here, such as our ability to obtain adequate coverage and reimbursement for our tests from third party payors, our ability to obtain necessary regulatory clearances and approvals, the ability of our tests to keep pace with rapid advances in technology, medicine and science, and our ability to execute our marketing strategy and gain acceptance in the market, along with those other risks and uncertainties detailed in our SEC filings, and involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date this release and we assume no obligation to update or revise these statements unless otherwise required by law.
|SIGNAL GENETICS, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|(in thousands, except share and par value data)|
|Cash||$ 10,448||$ 5,119|
|Accounts receivable, net||581||1,088|
|Prepaid expenses and other current assets||294||399|
|Total current assets||11,859||6,785|
|Property and equipment, net||1,192||1,214|
|Deferred offering costs||—||47|
|Total assets||$ 13,094||$ 8,089|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable||$ 332||$ 255|
|Note payable – related party||1,105||—|
|Amounts due to related party||—||1,045|
|Lease termination/abandonment payable - current portion||63||248|
|Other current liabilities||98||80|
|Total current liabilities||2,075||1,989|
|Other noncurrent liabilities||76||109|
|Commitments and contingencies|
|Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding at June 30, 2015 or December 31, 2014||—||—|
|Common stock, $0.01 par value, 50,000,000 shares authorized, 7,845,530 and 3,782,629 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively||78||38|
|Additional paid in capital||22,701||12,593|
|Total stockholders' equity||10,943||5,991|
|Total liabilities and stockholders' equity||$ 13,094||$ 8,089|
|SIGNAL GENETICS, INC.|
|UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except share and per share data)|
Three Months Ended
Six Months Ended
|Net revenue||$ 734||$ 1,274||$ 1,378||$ 2,364|
|Cost of revenue||678||954||1,439||1,685|
|Selling and marketing||574||66||1,008||132|
|Research and development||194||128||293||162|
|General and administrative||1,778||2,937||3,740||3,363|
|Total operating expenses||3,224||4,085||6,480||5,342|
|Loss from operations||(2,490)||(2,811)||(5,102)||(2,978)|
|Net loss attributable to stockholders of Signal Genetics, Inc.||(2,562)||(2,745)||(5,196)||(2,745)|
|Net loss attributable to members of Signal Genetics LLC||(544)||(1,250)|
|Net loss attributable to stockholders of Signal Genetics, Inc./member of Signal Genetics LLC||$ (2,562)||$ (3,289)||$ (5,196)||$ (3,995)|
|Net loss per common share, basic and diluted||$ (0.33)||$ (4.73)||$ (0.77)||$ (8.92)|
|Weighted-average number of shares outstanding, basic and diluted||7,785,670||695,454||6,789,376||447,727|
|SIGNAL GENETICS, INC.|
|UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
Six Months Ended
|Net loss||$ (5,196)||$ (3,995)|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||90||72|
|Noncash interest on note payable – related party||88||1,008|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other current assets||105||(25)|
|Accounts payable and other current liabilities||233||78|
|Lease termination/abandonment payable||(185)||(243)|
|Net cash used in operating activities||(3,295)||(385)|
|Purchases of property and equipment||(68)||(4)|
|Net cash used in investing activities||(68)||(4)|
|Proceeds from issuance of common stock, net of costs to issue||9,074||7,113|
|Proceeds from issuance of note payable/amounts due to related party||—||795|
|Shares repurchased to satisfy tax withholding obligation for restricted stock award||(346)||—|
|Repayment of capital lease obligation and note payable||(36)||(32)|
|Net cash provided by financing activities||8,692||7,876|
|Net increase in cash||5,329||7,487|
|Cash, beginning of period||5,119||209|
|Cash, end of period||$ 10,448||$ 7,696|
CONTACT: INVESTOR CONTACT: The Ruth Group David Burke Tel: 646-536-7009 firstname.lastname@example.orgNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...